Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

CardioLogical Solutions obtains additional patents for its aortic embolic protection devices

Cardiovascular device company CardioLogical Solutions has obtained two additional patents for its family of aortic embolic protection devices, developed to prevent stroke and other ischemic complications.

The first patent is issued for its Emboline CAP technology, while the second patent for its broad embolic deflector intellectual property portfolio.

With these two additional patents, the company now has four issued patents for aortic embolic protection.

The aortic embolic protection technologies of Emboline and the large-hole access and closure technologies of VasoStitch, derived from intellectual property invented by serial entrepreneur Dr Amir Belson, form the initial core of a suite of accessory devices offered by the company to address the clinical needs of emerging interventional cardiology procedures.

CardioLogical Solutions CEO David W J Smith noted these newly issued patents afford the company additional IP protection for its critical accessory technologies aimed at the transcatheter aortic valve implantation (TAVI) community today.

"Indeed, our two initial platforms of procedural accessory devices address the most pressing clinical needs in the rapidly growing evolution of TAVI therapies: specifically, a dire need for nonsurgical, large-hole (>12 Fr) access and closure technologies, and aortic embolic protection devices for prevention of stroke and other ischemic complications," Smith added.

Currently, the company is in advanced stages of raising Series B financing to obtain CE Mark for its initial Emboline and VasoStitch products, and is expected to begin initial commercial sales in the ninth calendar quarter following the close of funding.

The company plans to launch the first VasoStitch product, followed by the first Emboline device approximately after six months in Europe.